Gunderson Dettmer has advised BrainChild Bio. BrainChild Bio, a clinical-stage biotechnology company, has announced the closure of a $116 million Series A financing round. The financing...
BrainChild Bio Raises $116 Million in Series A Financing
Leyden Labs Acquires RIGImmune to Expand Airway-Targeted Medicines Portfolio
Gunderson Dettmer has advised RIGImmune in its acquisition by Leyden Labs. Leyden Laboratories B.V. has completed its acquisition of RIGImmune, a biopharmaceutical company specializing in immune...
Emerald AI Secures $150 Million Series A Funding at $1.05 Billion Valuation
Gunderson Dettmer has advised Emerald AI. Emerald AI has completed an oversubscribed Series A financing round, securing $150 million at a valuation of $1.05 billion. Emerald...
Amplitude Therapeutics and Lilly Announce Strategic RNA Vaccine Collaboration
Gunderson Dettmer has advised Amplitude Therapeutics. Amplitude Therapeutics has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company (Lilly) to develop...
Dataminr’s $100 Million Convertible Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Dataminr in the transaction. Dataminr, a global leader in AI-powered real-time information platforms, announced it has secured a...
Newleos Therapeutics’ $93.5 Million Series A Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Newleos Therapeutics in the transaction. Newleos Therapeutics, a clinical stage neuroscience company co-founded by Longwood Fund and seasoned...
OraSure Technologies’ Acquisition of Sherlock Biosciences
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Sherlock Biosciences in the transaction. OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests...
Photys Therapeutics’ $186 Million Research Collaboration with Novo Nordisk
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Photys Therapeutics in the transaction. Photys Therapeutics (Photys), a proximity-based therapeutics company, announced its multi-year collaboration and license...
Metsera’s $215 Million Series B Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Wellington Management in the transaction. Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity...
ArsenalBio’s $325 Million Series C Financing Round
Cooley, Goodwin Procter and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Arsenal Biosciences on the transaction. Arsenal Biosciences (ArsenalBio) announced raising $325 million in Series...
Cultivo’s $14 Million Series A Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented MassMutual Ventures in the transaction. Cultivo announced it raised $14 million in Series A financing, to accelerate its mission...
Prove Identity’s $40 Million Funding Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented MassMutual Ventures in the transaction. Prove Identity announced $40 million funding round led by MassMutual Ventures and Capital One Ventures. The...